Big pharma joins forces to form National Immunotherapy Coalition

12 January 2016

Some of the biggest players in the cancer drug making industry have formed an historic alliance in an effort to accelerate the potential of combination immunotherapies, it has been announced.

The National Immunotherapy Coalition (NIC), a Cancer Moonshot 2020 initiative, was launched at the annual JP Morgan Healthcare Conference in San Francisco on Monday (January 11).

The unprecedented collaboration will see large pharmaceutical companies such as GlaxoSmithKline (LSE: GSK), Amgen (Nasdaq: AMGN) and Celgene (Nasdaq: CELG) and biotech companies including NantWorks, NantKwest and Precision Biologics, join forces with community oncologists and some of the biggest academic centers in the US.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK